Introduction
Here’s how Chinese patent invalidation worked before January 2026: a competitor challenges your patent. CNIPA reviews the case. You survive. The competitor files again with slightly modified arguments — different prior art combinations, tweaked claim construction positions, minor variations on the same theme. And again. And again. Your patent is valid, but its enforceability is perpetually uncertain because proceedings never quite end.
This wasn’t an edge case. Serial invalidation campaigns were a recognised feature of Chinese patent litigation — used not just to challenge weak patents on merit, but as a competitive tool to keep a rival’s patent locked in proceedings and commercially unreliable. The previous rule barred challenges based on ‘the same reasons and evidence’ — interpreted so narrowly that even minimally modified arguments could restart the process.
On January 1, 2026, CNIPA’s revised Patent Examination Guidelines changed this. The new standard bars challenges based on ‘the same or substantially the same reasons and evidence.’ One word added. Everything about Chinese invalidation strategy changes with it. This article covers what the reform means, what the data shows about Chinese invalidation outcomes, and how both challengers and patent holders need to rebuild their approach.
The Problem the Reform Was Designed to Fix
To understand why the reform matters, you need to understand the environment it was addressing.
Chinese patent invalidation proceedings are handled by the CNIPA’s Reexamination and Invalidation Department. Globally, China’s approach to patent invalidation sits alongside the US PTAB and the EPO’s Opposition Division as one of the three major post-grant challenge mechanisms in the world. In terms of volume, CNIPA now handles more invalidation requests than either PTAB or the EPO.
Two structural problems had developed in the Chinese invalidation system that the 2026 reform directly targets:
- Serial challenge campaigns. The narrow interpretation of ‘same reasons and evidence’ allowed competitors to file essentially identical arguments with minor variations — a different prior art combination, a slightly different claim construction framing, a new expert declaration on the same prior art. Each filing restarted the proceedings. A patent could be kept in a state of perpetual uncertainty for years, regardless of its underlying validity.
- Straw-man filings. Chinese competitors discovered they could circumvent the practical restrictions on serial challenges by using third parties — sometimes completely unrelated to the dispute — to file invalidation requests on their behalf. The nominal requestor had no stake in the outcome. The actual challenger maintained strategic distance from the proceeding. This made it nearly impossible to link serial challenges to a single bad-faith actor.
The reform addresses both directly. The substantially same evidence standard closes the serial challenge loophole. The anti-straw-man rule closes the identity loophole.
The New ‘Substantially Same Evidence’ Standard: What It Means in Practice
Let’s be precise about what the 2026 revision actually says.
The revised guidelines prohibit new invalidation requests based on ‘the same or substantially the same reasons and evidence’ as a prior CNIPA decision. The key word is ‘substantially.’ The reform is explicitly designed to close the gap between ‘identical’ and ‘similar enough to constitute the same challenge.’
Old standard: New invalidation request barred only if based on the exact same reasons and evidence as a prior CNIPA decision. Minor variations in prior art combinations, framing, or argument structure were treated as different enough to permit a new filing.
New standard: New invalidation request barred if based on the same OR substantially the same reasons and evidence. The question is not whether the filing looks different on the surface — it’s whether it is substantively the same challenge.
The one exception: reasons or evidence that were not considered in the prior proceeding due to time limits or procedural constraints. If the prior proceeding was time-limited and a challenger genuinely could not introduce certain evidence within that constraint, the new standard does not bar a subsequent filing on those specific grounds. Everything else is covered.
The practical consequence is fundamental: the first invalidation filing is now the most strategically important document in a Chinese patent challenge. There may not be a second attempt. Every piece of prior art, every argument, every claim construction position needs to be included in the first submission — not held back for a follow-up filing when the initial challenge doesn’t produce the desired outcome. The staged approach to Chinese invalidation — common under the old rules — is no longer viable.
The Anti-Straw-Man Rule: Ending Identity-Based Manipulation
The second major reform target is the straw-man filing problem. The 2026 guidelines address it with a direct prohibition and enforcement mechanism.
Under the revised guidelines, an invalidation request will be rejected if it does not reflect the true intention of the requester. Evidence that a request was filed at the instruction of another party, or that the requester’s identity is false, results in rejection of the filing. The requestor must be the genuine challenger — not a proxy acting at another party’s direction.
Two enforcement mechanisms back this up:
- Patent agency identity verification. Patent agencies are now legally required to verify applicant identity before filing an invalidation request on a client’s behalf. The agency cannot simply accept a client’s instruction to file in a third party’s name without verifying that the third party is the genuine requester.
- Agency liability. Patent agencies that file invalidation requests in their own names — a mechanism that had been used to mask the identity of the true challenger — face explicit penalties under the revised guidelines. Using the agency’s own identity as a shield for an undisclosed client is now a regulatory violation.
For patent holders: this provides a procedural defence against serial invalidation campaigns run through proxies. If you can demonstrate that an invalidation request was filed at the direction of a competitor — and that the nominal requestor had no genuine stake in the proceeding — the filing is subject to rejection. That’s a meaningful protection that didn’t exist under the old rules.
For challengers: the identity and genuineness of the requestor must be clear and verifiable before filing. Using a third party as a nominal challenger to avoid the substantially same evidence bar — or to preserve strategic distance from a serial campaign — is now explicitly prohibited and enforceable.
The Data: What Chinese Invalidation Outcomes Actually Look Like
Before rebuilding your Chinese invalidation strategy, it helps to understand what the data shows about outcomes in CNIPA proceedings.
60% of challenged patents are completely invalidated 26% of patents survive unchanged 14% receive partial invalidation 131 days average timeline for maintained patents 279 days average timeline for partial invalidations
Let’s put that in context. A 60% complete invalidation rate is significantly higher than the equivalent figures at the US PTAB (where complete claim cancellation in IPR is less common than partial outcomes) or at the EPO Opposition Division. Chinese invalidation is highly effective for challengers when done well — but the key phrase is ‘when done well.’
Under the new standard, that effectiveness depends entirely on the quality of the first filing. A weak first filing that fails — with thin prior art, inadequate claim construction, or arguments that don’t map cleanly to claim elements — is now effectively a final loss. The 60% success rate was achieved in an environment where challengers had multiple shots at the target. Under the substantially same evidence standard, the challenge that succeeds will be the one that was built to succeed from the first submission.
The ‘Last Version Prevails’ Amendment Rule
The 2026 guidelines also change the rules for patent holders defending against invalidation — and this change gets less attention than the substantially same evidence standard but has equally significant practical implications.
Under the revised guidelines, where a patent holder submits amended claims during an invalidation proceeding, only the last version of the amended claims counts. Amended claims must be submitted with full replacement pages and a comparison table. Where multiple amended texts are submitted in the same proceedings, the last version replaces all previous versions.
This closes a defensive strategy that had become common: submitting multiple alternative claim sets during the proceeding — narrow claims, medium claims, broad claims — and then watching which arguments the challenger deployed before selecting the most favourable version. Under the last version prevails rule, that optionality is gone.
The practical implication for patent holders: the final claim version must be the strongest version, submitted only when the patent holder is confident in its scope and validity against the specific prior art the challenger has deployed. There is no longer a backstop of holding alternative claim versions in reserve. The claim amendment decision is now a one-shot choice, not a staged negotiation.
“The 2026 CNIPA reform is a fundamental rebalancing. It protects patent holders from serial attacks while simultaneously raising the bar for the quality of the first challenge. For both sides, the prior art search that feeds the first filing is no longer preparation — it is the strategy.”
How to Rebuild Your Chinese Invalidation Strategy for the New Environment
The 2026 reform changes the approach for both challengers and patent holders. Here’s what the adjusted strategy looks like on each side.
For Patent Challengers: The One-Shot Approach
The staged invalidation approach — run a targeted search, file an initial challenge, develop the full prior art case if the initial challenge gains traction — is no longer viable under the substantially same evidence standard. Everything needs to be in the first filing.
- Commission a comprehensive prior art search before filing. Multi-database, multi-language, covering CNIPA, JPO, USPTO, Espacenet, NPL, and non-patent literature. The search needs to be comprehensive enough that every potentially relevant reference is identified and assessed before a single argument is committed to the filing.
- Build the claim chart for each independent claim before filing. Element-by-element mapping of prior art to claim limitations, constructed under the Chinese claim construction standard. Don’t file without the charts. A reference without a claim chart is nearly useless in a CNIPA proceeding.
- Include all viable prior art combinations in the first filing. Anticipation arguments, obviousness combinations, and prior use evidence — all in the first submission. Don’t hold back combinations that you think are ‘secondary.’ Under the new standard, you won’t get a second chance to use them.
For Patent Holders: Pre-Challenge Validity Pre-Screening
The best time to understand your Chinese patent’s validity exposure is before an invalidation request is filed against it — not in response to one.
- Commission validity pre-screening for commercially important Chinese patents. Identify the most likely prior art before a challenger does. This gives you time to consider claim amendments, continuation strategy, or commercial resolution before proceedings begin under the compressed last-version-prevails rules.
- Identify which patents are most likely to face challenge. Commercially active Chinese patents in technology areas with high filing activity are the most exposed. Map your portfolio against the competitive landscape to identify the highest-risk assets.
- Prepare amended claim sets in advance. Under the last version prevails rule, the decision to amend needs to be made with confidence. Having alternative claim versions developed and assessed before a challenge arrives means the amendment decision can be made strategically, not reactively.
For a broader perspective on how invalidation strategy differs across the major global jurisdictions — CNIPA, PTAB, and EPO — and how prior art strategy needs to account for those differences, our guide on key strategies and insights for invalidity searches covers the methodology in detail.
How Our Patent Invalidation Search Service Supports the New Chinese Environment
Our patent invalidation search service is built around the one-shot requirement that the 2026 CNIPA reform creates. For companies filing invalidation requests in China, we deliver prior art searches that cover CNIPA, JPO, USPTO, Espacenet, and NPL sources in a single comprehensive engagement — structured to include every potentially relevant reference in the first submission rather than held in reserve for follow-up filings that may no longer be available.
Every engagement starts with claim construction under the Chinese examination standard — parsing each independent claim before a single database is searched. The search covers patent databases in Chinese (CNIPA native interface), Japanese (J-PlatPat), English (USPTO, Espacenet, WIPO PATENTSCOPE), and Korean (KIPO), plus NPL sources including academic databases, conference proceedings, and technical standards. Foreign language documents are reviewed directly by native-language analysts — not machine translation only.
The output is a CNIPA-ready invalidity report: element-by-element claim charts for each relevant reference, a clear mapping of which references anticipate claims outright and which render claims obvious in combination, and a prosecution history review identifying arguments made during CNIPA examination that define the claim boundaries. Under the 2026 standard, this is the document that matters — and it needs to be right the first time.
China’s new invalidation rules make the first filing decisive. Our patent invalidation search service delivers the comprehensive, claim-charted prior art case that the 2026 CNIPA standard demands — built for a single, complete submission, not a staged campaign. → Contact Us
Conclusion: The Takeaway
The 2026 CNIPA reform is a fundamental rebalancing of Chinese patent invalidation. It protects patent holders from the serial attack campaigns that made Chinese patent rights commercially unreliable. It raises the bar for challengers to build their full case in a single, comprehensive submission. And it closes the identity-based manipulation that allowed bad-faith challengers to hide behind proxies.
For both sides, the consequence is the same: the prior art search that feeds the first filing is no longer preparation — it is the strategy. A weak first filing under the new standard isn’t a starting point for a staged challenge. It’s a final loss. And a patent holder who hasn’t pre-screened their Chinese assets doesn’t know whether the challenge that’s coming will be stopped at the first attempt or whether their patent has the vulnerabilities to sustain it.
The rules changed on January 1, 2026. The strategy needs to change with them.
